Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
This paper by Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital, Sweden, highlights the importance of chimerism as a diagnostic tool for clinicians treating transplanted patients. Furthermore, the evolution of novel diagnostic tools for early detection of mixed chimerism is discussed. The recent development of NGS technology offers the possibility to analyze mixed chimerism with both sensitivity, as well as accurate and precise determination.
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More